IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Margaretha Grind)	Confirmation No. 1056
Application No. 10/550,154)	Group Art Unit: 1654
Filed: September 20, 2005)	Examiner: Hemant Khanna, Ph.D.
For: Use of Low Molecular Weight Thrombin Inhibitors in Cholesterol-Lowering Therapy)	Dated: August 29, 2007

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants request the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or

credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Dated: August 29, 2007 Morgan, Lewis & Bockius LLP Customer No. 09629 1111 Pennsylvania Ave., N.W. Washington, D.C. 20004

Tele: 202-739-3000 Fax: 202-739-3001 Respectfully submitted

Morgan, Lewis & Bockius LLP

Gregory T. Ldwen Registration No. 46,882 Direct: 202-739-5915

INFORMATION DISCLOSURE CITATION			Attorney Docket	056291-5256	Application	Application No. 10/550,154				
(Use several sheets if necessary)			Applicant: Margaretha Grind			Page 1 of				
PTO Form 1449 (August 29, 2007)			Filing Date: Septe	ember 20, 2005	Group Art U	Group Art Unit: 1654				
			U.S. PAT	TENT DOCUMENT	S					
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date			
			FOREIGN		DIEC					
	T	Document No.	Date	PATENT DOCUME Country	Class	Sub-Class	TI-4!			
/MA/	aa	WO 93/11152	06/10/1993	WIPO	Class	Sub-Class	Translation			
	ab	WO 97/40024	10/30/1997	WIPO						
ullet	ac	WO 98/37075	08/27/1998	WIPO						
/MA/	ad	WO 02/44145 A1	06/06/2002	WIPO						
				ing Author, Title, D			***************************************			
/MA/	ae	Eriksson et al. (2003) Direct Thrombin Inhibitor Melagatran Followed by Oral Ximelagatran in Comparison With Enoxaparin for Prevention of Venous Thromboembolism After Total Hip or Knee Replacement, Thrombosis and Haemostasis, 89(2):288-296, CAS Abstract No. 138:280930								
/MA/	af	Shinji et al. (1994) Preparation of Aminated Fucoidan and its Evaluation as an Antithrombotic and Antilipemic Agent, Biological & Pharmaceutical Bulletin, 17:784-788, Biosis Abstract No. PREV199497516777								
/MA/	ag	Szczeklik et al. (1999) Inhibition of Thrombin Generation by Simvastatin and Lack of Additive Effects of Aspirin in Patients With Marked Hypercholesterolemia, J. Am. College of Cardiology, 33(5):1286-1293, Medline Abstract Acc. No. NLM10193729								
	<u></u>									
Examine	r	/Maury Audet/	Date	Considered _{04/14}	4/2008					
Examine	er: Initi	al if reference considered, vand not considered. Include	whether or not cit	ation is in conforman	ce with MPEP 6	09; draw line thr	ough citation if no			

-WA/2816973.1